Use of Prostate-Specific Antigen to Predict Pathologic Types in Nodular Benign Prostate Hyperplasia

LI Gui-zhong,LIU Liu,HUANG Guang-lin,WANG Jian-wei,LIU Ning,MAN Li-bo,HE Feng,WANG Hai,YUAN Yi-ming,YANG Xin-yu,XIA Tong-li,NA Yan-qun
DOI: https://doi.org/10.3760/j:issn:1000-6702.2006.11.009
2006-01-01
Abstract:Objective To determine the value of clinical testing of prostate-specific antigen ( PSA) to predict pathologic types in nodular benign prostate hyperplasia (BPH). Methods The data of 210 consecutive patients with clinically and pathologically proven BPH were retrospectively analyzed. Results According to histopathologic findings,stromal nodule,acinar smooth muscle nodule, fiber acinar nodule,acinar nodule and mixed nodule were found in 18 cases (9% ) ,59 (28% ) , 12 (6% ) , 39 ( 19% ) and 82 (39% ) ,respectively. The differences in total PSA (tPSA) and free PSA (fPSA) levels were significant a-mong the 5 groups of BPH types (P 0. 05) ;while the difference in percentage of fPSA was not significant ( P 0. 05 ) . There were significant differences of tPSA and fPSA between histologic types ( primarily glandular or stromal hyperplasia) in BPH ( P 0. 05) , but no significant difference in percentage of fPSA ( P 0.05). In multivariate analysis, tPSA was the only significant predictors of pathologic types of nodules in BPH. A model was constructed to predict pathologic types in BPH. If tPSA≥2.5 ng/ml (cut-off value of sensitivity) ,the sensitivity,specificity and area under ROC Curve were 96% ,20% and 0. 61 ,respectively. If tPSA≥2.5 ng/ml combined with fPSA≥0.5 ng/ml, the sensitivity, specificity and area under ROC Curve were 100% ,67% and 0.91, respectively (P 0.001). Conclusions The combination of tPSA and fPSA provides the best prediction of pathologic types in BPH. Treatment regimens based on this combination of factors may be clinically useful to stratify patients for drug options.
What problem does this paper attempt to address?